Cambridge Investment Research Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,505	Closed	-$34K	–	3985
2026 Q1	$34K	Hold	21,505	–	–	﹤0.01%	3876
2025 Q4	$25K	Sell	21,505 -1,895	-8%	-$2.6K	﹤0.01%	3785
2025 Q3	$32K	Buy	23,400 +1,900	+9%	+$2.16K	﹤0.01%	3676
2025 Q2	$20K	Sell	21,500 -575	-3%	-$373	﹤0.01%	3579
2025 Q1	$10K	Sell	22,075 -1,538	-7%	-$970	﹤0.01%	3484
2024 Q4	$17K	Buy	+23,613	New	+$28.5K	﹤0.01%	3430
2023 Q4	–	Sell	-14,239	Closed	-$16K	–	3260
2023 Q3	$16K	Buy	+14,239	New	+$25K	﹤0.01%	3093
2015 Q2	–	Sell	-15,086	Closed	-$100K	–	1467
2015 Q1	$100K	Hold	15,086	–	–	﹤0.01%	1339
2014 Q4	$96K	Buy	+15,086	New	+$122K	﹤0.01%	1297

Other funds holding LXRX

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SPWM

Straight Path Wealth Management Jenison, Michigan $428M AUM 26.3% 1-Year Est. Return

FGA

Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Cambridge Investment Research Advisors's LXRX Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 21,505 shares — an estimated $34K sold.

Cambridge Investment Research Advisors first reported a position in LXRX in Q4 2014 and held it in 9 quarters. The position peaked at $100K in Q1 2015. 16 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

Cambridge Investment Research Advisors reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cambridge Investment Research Advisors sold 21,505 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $34K.
Cambridge Investment Research Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Cambridge Investment Research Advisors's Lexicon Pharmaceuticals position peaked at $100K in Q1 2015.
16 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.